CALGARY,
AB and TORONTO,
May 23,
2024 /PRNewswire/ - Providence Therapeutic
Holdings Inc. ("Providence"), a messenger RNA (mRNA) and lipid
nanoparticle platform company engaged in the development of
vaccines and therapeutics, and the Ontario Institute for Cancer
Research (OICR), Ontario's largest
publicly funded cancer research institute delivering real-world
solutions to people affected by cancer, today announced the signing
of a collaboration agreement for mRNA drug discovery and
development. This is a unique collaboration that combines OICR's
expertise in cancer genomics and translational drug discovery with
Providence's next generation of
mRNA and LNP technology to accelerate preclinical drug development
and launch new clinical initiatives that answer key questions in
clinical oncology.
"OICR and Providence share a
common vision of advancing research in cancer prevention and
treatment in Ontario, across
Canada, and globally. We look
forward to leveraging Providence's
next generation mRNA and LNP platform technology and drug
development expertise alongside the experts at OICR to improve the
lives of people battling cancer," said Brad
Sorenson, CEO and Founder of Providence Therapeutics.
"Partnering with an mRNA industry leader like Providence will help OICR harness our
strengths in bioinformatics, genomics and immunology to generate
new and exciting ways to prevent and treat cancer," says Dr.
Laszlo Radvanyi, President and
Scientific Director of OICR. "I am especially excited for the
impact this partnership will have for people affected by cancer as
well as the potential economic value it can bring in helping drive
Canada's leadership in this
rapidly growing field."
OICR and Providence's
partnership will help advance modern drug development in
Canada and create new clinical
initiatives that will touch the lives of people across the country.
As product development and manufacturing will be done domestically,
Canadians will be first in line to participate in new clinical
oncology programs and access new treatments.
All programs that emerge from this strategic partnership will
result in guaranteed country-of-origin rights to Canada that will ensure Canadians will have
affordable access to any medicines created.
About Providence
Therapeutics
Providence Therapeutics has developed an mRNA medicines platform
and has established itself as a competitive player within the mRNA
scene for the last 10 years. Consisting of a clinically proven mRNA
platform and a next-generation lipid-nanoparticle (LNP) platform,
the company developed to enhance immune responses to cancers and
infectious diseases. Along with this, Providence also has manufacturing and
regulatory platforms that are capable of producing drugs for
personalized vaccines up to pandemic scale amounts. Providence has a robust pipeline consisting of
preclinical and clinical oncology, infectious diseases, and animal
health programs. These programs have been developed internally and
in collaboration with academic and industry partners that
specialize in many different fields. For more information, please
visit https://providencetherapeutics.com
About Ontario Institute for Cancer
Research
OICR is funded by the Government of Ontario. As the province's cancer research
institute, we take on the biggest challenges in cancer research and
deliver real-world solutions to find cancer earlier and treat it
more effectively. We are committed to helping people living with
cancer, as well as future generations, live longer and healthier
lives. For more information visit http://www.oicr.on.ca.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/providence-and-ontario-institute-for-cancer-research-oicr-partnering-to-discover-and-develop-mrna-therapeutics-302153648.html
SOURCE Providence Therapeutics